» Authors » Muthu K Shanmugam

Muthu K Shanmugam

Explore the profile of Muthu K Shanmugam including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 103
Citations 5218
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Ren B, Kwah M, Liu C, Ma Z, Shanmugam M, Ding L, et al.
Cancer Lett . 2021 May; 515:63-72. PMID: 34052324
Resveratrol (3,4',5-trihydroxy-trans-stilbene) has been expected to ameliorate cancer and foster breakthroughs in cancer therapy. Despite thousands of preclinical studies on the anticancer activity of resveratrol, little progress has been made...
12.
Shanmugam M, Dharmarajan A, Warrier S, Bishayee A, Kumar A, Sethi G, et al.
Adv Protein Chem Struct Biol . 2021 May; 125:149-191. PMID: 33931138
The development of cancer is a complex phenomenon driven by various extrinsic as well as intrinsic risk factors including epigenetic modifications. These post-translational modifications are encountered in diverse cancer cells...
13.
Shanmugam M, Garg M, Makhija P, Kumar A, Sharifi-Rad J, Zam W, et al.
Curr Mol Pharmacol . 2021 Feb; 14(5):806-822. PMID: 33573586
Background: Medicinal plants and herbal preparations in the form of traditional medicines have been used in healthcare worldwide. The extracts of Ginkgo biloba L. seeds and leaves contain a complex...
14.
Garg M, Shanmugam M, Bhardwaj V, Goel A, Gupta R, Sharma A, et al.
Med Res Rev . 2020 Dec; PMID: 33289118
Signal transducer and activator of transcription 3 (STAT3) is one of the crucial transcription factors, responsible for regulating cellular proliferation, cellular differentiation, migration, programmed cell death, inflammatory response, angiogenesis, and...
15.
Malojirao V, Girimanchanaika S, Shanmugam M, Sherapura A, Dukanya , Metri P, et al.
Biomedicines . 2020 Sep; 8(9). PMID: 32967366
Lung cancer is the leading type of malignancy in terms of occurrence and mortality in the global context. STAT3 is an oncogenic transcription factor that is persistently activated in many...
16.
Dukanya , Shanmugam M, Rangappa S, Metri P, Mohan S, Basappa , et al.
Data Brief . 2020 Jul; 31:105979. PMID: 32715036
This data in brief article explains the anti-cancer activity and characterization of oxadiazoles [1]. The main objective of this article was to provide general synthetic procedures, spectral discussion and physical...
17.
Dukanya , Shanmugam M, Rangappa S, Metri P, Mohan S, Basappa , et al.
Bioorg Med Chem Lett . 2020 Jul; 30(16):127330. PMID: 32631535
A novel series of indazole tethered oxadiazoles (OTDs) derivatives were synthesized, characterized and screened for their anti-proliferative activity against hepatocellular carcinoma (HCC) cells. OTDs structure was further confirmed by Single-crystal...
18.
Lee J, Mohan C, Shanmugam M, Rangappa S, Sethi G, Siveen K, et al.
Biochimie . 2020 May; 175:58-68. PMID: 32445654
Hepatocellular carcinoma (HCC) is a major malignancy that stands second in terms of global cancer-related mortality. STAT3 has been described as a latent transcription factor that promotes tumorigenesis. This study...
19.
Somu C, Mohan C, Ambekar S, Dukanya , Rangappa S, Baburajeev C, et al.
Biotechnol Rep (Amst) . 2020 Mar; 25:e00438. PMID: 32140443
Constitutive activation of NF-κB is associated with proinflammatory diseases and suppression of the NF-κB signaling pathway has been considered as an effective therapeutic strategy in the treatment of various cancers...
20.
Wang W, Shanmugam M, Xiang P, Yam T, Kumar V, Chew W, et al.
Cancers (Basel) . 2020 Jan; 12(1). PMID: 31952197
Ototoxicity is a major adverse effect of platinum-based chemotherapeutics and currently, there remains a lack of United States Food and Drug Administration-approved therapies to prevent or treat this problem. In...